<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744820</url>
  </required_header>
  <id_info>
    <org_study_id>GMC-252-1.03</org_study_id>
    <nct_id>NCT02744820</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics</brief_title>
  <official_title>A Double Blind, Placebo-controlled, Randomised, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GMC-252 in Healthy Male Subjects and Male Type 2 Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmedica Therapeutics S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genmedica Therapeutics S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of&#xD;
      multiple oral doses of GMC-252-L-Lysine salt (GMC-252) in healthy subjects and type 2&#xD;
      diabetics.&#xD;
&#xD;
      The secondary objective is to explore the effect of multiple oral doses of GMC-252 on&#xD;
      pharmacodynamic(PD) parameters in type 2 diabetics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    It was considered by the sponsor that the study objective has been met by dosing 13 instead of&#xD;
    15 patients&#xD;
  </why_stopped>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
    <description>Physical status (Vital signs; 12-lead ECG; Urinalysis; Haematology and biochemistry)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal Concentration (Cmax)</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach steady state</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Preliminary effect on Fasting blood glucose (Cohort 4 only)</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Preliminary effect on oral glucose tolerance test (OGTT) (Cohort 4 only)</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Preliminary effect on Insulin levels (Cohort 4 only)</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
    <description>Insulin</description>
  </other_outcome>
  <other_outcome>
    <measure>Preliminary effect on C-Peptide levels (Cohort 4 only)</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Preliminary effect on Fructosamine levels (Cohort 4 only)</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Preliminary effect on %HbA1c (Cohort 4 only)</measure>
    <time_frame>28 days plus 14 days post last dose</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo&#xD;
Interventions:&#xD;
Drug: GMC-252-L-Lysine Salt Other: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo&#xD;
Interventions:&#xD;
Drug: GMC-252-L-Lysine Salt Other: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo&#xD;
Interventions:&#xD;
Drug: GMC-252-L-Lysine Salt Other: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (Part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo&#xD;
Interventions:&#xD;
Drug: GMC-252-L-Lysine Salt Other: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMC-252-L-Lysine Salt</intervention_name>
    <description>1 dose by oral route, once a day, 28 days</description>
    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 3 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 4 (Part 2)</arm_group_label>
    <other_name>GMC-252-L-Lys Salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching doses by oral route, once a day, 28 days</description>
    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 3 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 4 (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Part 1 (Healthy Subjects) and Part 2 (Type 2 Diabetic Patients):&#xD;
&#xD;
          1. Diet: Able to eat standard food, no vegetarians.&#xD;
&#xD;
          2. Compliance: Understands and is willing, able and likely to comply with all study&#xD;
             procedures and restrictions.&#xD;
&#xD;
          3. Consent: Demonstrates understanding of the study and has given signed, voluntary&#xD;
             written informed consent.&#xD;
&#xD;
          4. Have no known hypersensitivity to diflunisal, NAC or other NSAIDs.&#xD;
&#xD;
          5. No history of blood diseases including but not limited to clinically significant&#xD;
             platelet diseases and coagulation abnormalities.&#xD;
&#xD;
          6. No clinically relevant gastrointestinal disease.&#xD;
&#xD;
          7. Have an estimated creatinine (CREA) clearance&gt;70 mL/min/surface area (CREA clearance&#xD;
             will be calculated from the serum CREA value by using the Cockroft and Gault formula).&#xD;
&#xD;
          8. Have no history of heart failure or uncontrolled hypertension or other known&#xD;
             clinically significant cardiovascular disease.&#xD;
&#xD;
          9. Have no history of bronchial asthma or 'Aspirin Triad' (chronic rhino-sinusitis with&#xD;
             polyps, severe asthma and intolerance to aspirin or other NSAIDs).&#xD;
&#xD;
         10. Have no clinically significant abnormality of liver tests before entry into the study.&#xD;
&#xD;
         11. A negative urinary drugs of abuse screen, determined within 28 days before the first&#xD;
             dose (N.B. a positive alcohol result may be repeated at the discretion of the&#xD;
             Investigator).&#xD;
&#xD;
         12. Negative human immunodeficiency virus (HIV) and hepatitis B surface antigen (Hep B)&#xD;
             and hepatitis C virus antibody (Hep C) results.&#xD;
&#xD;
         13. No clinically significant abnormalities in a 12-lead ECG determined within 28 days&#xD;
             before the first dose.&#xD;
&#xD;
         14. No history of clinically significant renal disease or any food intolerance.&#xD;
&#xD;
         15. Willing to use 2 effective methods of contraception i.e. established method of&#xD;
             contraception + condom, if applicable (unless anatomically sterile or where abstaining&#xD;
             from sexual intercourse is in line with the preferred and usual lifestyle of the&#xD;
             subject) from Day 1 until 3 months afterwards.&#xD;
&#xD;
        Additional Criteria for Part 1 (Healthy Subjects):&#xD;
&#xD;
          1. Healthy males aged 18 to 55 inclusive.&#xD;
&#xD;
          2. Body mass index (BMI) within the range of 18-30 kg/m2 inclusive.&#xD;
&#xD;
          3. Non-Smokers (including e-cigarettes) who have abstained from smoking for at least 6&#xD;
             months.&#xD;
&#xD;
        Additional Criteria for Part 2 (Type 2 Diabetic Patients):&#xD;
&#xD;
          1. Males aged 18 to 65 inclusive. BMI within the range of 18-38 kg/m2 inclusive.&#xD;
&#xD;
          2. Diagnosis of T2DM according to the World Health Organization criteria.&#xD;
&#xD;
          3. HbA1c between 7.0% and 12.0 % inclusive.&#xD;
&#xD;
          4. Currently treated with metformin with a stable treatment regimen for 3 months or more&#xD;
             prior to the Screening Visit, and not receiving other anti-diabetic medications.&#xD;
             Allowed medication during the study include metformin, statin&#xD;
             (3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors), paracetamol up&#xD;
             to 3 g/day, low doses of aspirin and antihypertensive drugs if the doses are not&#xD;
             changed in the 3 months before the start of screening. Other allowed medications will&#xD;
             be approved by PI and Sponsor before a patient can be enrolled. Diflunisal (a test&#xD;
             drug component) may decrease the antihypertensive activityof many of the currently&#xD;
             used antihypertensive medications, such as β-blockers, alpha (α)-blockers, loop&#xD;
             diuretics, angiotensin converting enzyme (ACE inhibitors), angiotensin 2 receptor&#xD;
             blockers, calcium channel blockers. Therefore, patients who are on current stable&#xD;
             antihypertensive medications will be subjected to close monitoring of their blood&#xD;
             pressure throughout the study.&#xD;
&#xD;
          5. Stable dietary habits and regimen of treatment for concomitant diseases for 1 month or&#xD;
             more prior to the Screening Visit.&#xD;
&#xD;
          6. Subject able and willing to undergo oral glucose tolerance test (OGTT).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Part 1 (Healthy Subjects) and Part 2 (Type 2 Diabetic Patients):&#xD;
&#xD;
          1. A clinically significant history of previous allergy / sensitivity to any of the&#xD;
             GMC-252 components, NAC or diflunisal.&#xD;
&#xD;
          2. Inability to communicate well with the Investigator (i.e., language problem, poor&#xD;
             mental development or impaired cerebral function).&#xD;
&#xD;
          3. Participation in a New Chemical Entity clinical study within the previous 4 months or&#xD;
             a marketed drug clinical study within the previous 3 months. (N.B. washout period&#xD;
             between studies is defined as the period of time elapsed between the last dose of the&#xD;
             previous study and the first dose of the next study).&#xD;
&#xD;
          4. Donation of 450 mL or more blood within the previous 3 months.&#xD;
&#xD;
          5. A clinically significant history of drug, alcohol or other substance abuse in the past&#xD;
             2 years.&#xD;
&#xD;
        Additional Criteria for Part 1 (Healthy Subjects):&#xD;
&#xD;
          1. A clinically significant history of gastrointestinal disorder likely to influence drug&#xD;
             absorption.&#xD;
&#xD;
          2. Receipt of regular medication within 28days of the first dose that may have an impact&#xD;
             on the safety and objectives of the study (at the Investigator's discretion).&#xD;
&#xD;
          3. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or&#xD;
             metabolic dysfunction.&#xD;
&#xD;
        Additional Criteria for Part 2 (Type 2 Diabetic Patients):&#xD;
&#xD;
          1. Diagnosis/General Health:&#xD;
&#xD;
               -  Diabetic autonomic or sensory neuropathy including gastroparesis, diabetic&#xD;
                  nephropathy or untreated active proliferative retinopathy.&#xD;
&#xD;
               -  Clinically significant abnormalities in laboratory evaluation (including clinical&#xD;
                  biochemistry, haematology and urinalysis) in the opinion of the Investigator.&#xD;
&#xD;
          2. Diseases:&#xD;
&#xD;
               -  Uncontrolled hypertension (blood pressure ≥ 160/100 mmHg), severe or unstable&#xD;
                  angina, coronary insufficiency, congestive heart failure, clinically significant&#xD;
                  (in the opinion of the Investigator) renal or hepatic disease.&#xD;
&#xD;
               -  Previous gastric or intestinal surgerythat might impact drug absorption.&#xD;
&#xD;
               -  Malignancy within 5 years of the start of the study, except for successfully&#xD;
                  treated local basal cell carcinoma&#xD;
&#xD;
               -  Current or relevant previous history, of clinically significant psychiatric&#xD;
                  illness.&#xD;
&#xD;
          3. Medications:&#xD;
&#xD;
               -  Current use of insulin or any previous use of insulin other than as part of a&#xD;
                  clinical trial or associated with surgical procedure or acute illness for up to 7&#xD;
                  days.&#xD;
&#xD;
               -  Use of any anti diabetic medication other than metformin in the 3 months prior to&#xD;
                  study entry.&#xD;
&#xD;
               -  Current use of any anticoagulant drug e.g. warfarin, heparin.&#xD;
&#xD;
               -  Prior use (within 48 h of dosing) of any drug that could have altered gastric&#xD;
                  motility (domperidone, cyclizine, metoclopramide, prochlorperazine), or&#xD;
                  cholestyramine.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Adams, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioKinetic Europe Ltd.</name>
      <address>
        <city>Belfast</city>
        <zip>BT2 7BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simbec Research Ltd</name>
      <address>
        <city>Merthyr Tydfil</city>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

